InsidersTradesSigma
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (8 ops.)
Explore the detailed record of transactions filed by Tesi Raymond Joseph, Chairman & CEO. Director active across 1 companies, notably Inmune Bio, Inc.. In total, 12 filings have been logged. Total volume traded: €1.4m. The latest transaction was disclosed on 26 May 2022 — Acquisition. Regulator: SEC (Form 4). All data is accessible without signup.
Declarations12 total
€37,6256,300 shares@ €5.97230.091% mcap2.1% of flow
Common Stock
SEC:0001213900-22-030210:0·
Ideal exit: 20 Feb 2023 (T+270)
€181,52823,724 shares@ €7.65170.44% mcap10.2% of flow
Common Stock
SEC:0001213900-22-014507:0·
€62,6283,626 shares@ €17.2728.1% of flow
Common Stock
SEC:0001213900-21-056737·
€62,6283,626 shares@ €17.2720.15% mcap3.5% of flow
Common Stock
SEC:0001213900-21-056737:0·
€112,3616,517 shares@ €17.241214.5% of flow
Common Stock
SEC:0001213900-21-055422·
€112,3616,517 shares@ €17.24120.27% mcap6.3% of flow
Common Stock
SEC:0001213900-21-055422:0·
€406,28523,616 shares@ €17.203852.3% of flow
Common Stock
SEC:0001213900-21-054644·
€406,28523,616 shares@ €17.20380.99% mcap22.9% of flow
Common Stock
SEC:0001213900-21-054644:0·
€99,62330,000 shares@ €3.320812.8% of flow
Common Stock
SEC:0001213900-21-045373·
€99,62330,000 shares@ €3.32080.24% mcap5.6% of flow
Common Stock
SEC:0001213900-21-045373:0·
€95,8865,649 shares@ €16.973912.3% of flow
Common Stock
SEC:0001213900-21-036352·
€95,8865,649 shares@ €16.97390.23% mcap5.4% of flow
Common Stock
SEC:0001213900-21-036352:0·
12 of 12 declarations
About Tesi Raymond Joseph
Raymond Joseph Tesi is the Chairman & CEO of Inmune Bio, Inc. He leads the company with a focus on innovation in the biotechnology sector. Under his leadership, Inmune Bio is committed to developing therapeutic solutions to improve patient lives. His leadership is marked by a strategic approach and a strong results-oriented mindset.
